The Journal of Immunology · 2007 · 78 citations · 19 references
Life SciencesImmunologyMolecular BiologyInflammationInnate ImmunitySignal TransductionCytokine BiologyInflammatory BiomarkersInflammatory Cell ResponsesInflammatory SignalingMacrophage BiologyMetabolic InflammationAtherosclerosis-associated MacrophagesInflammation Response VariationInterindividual VariationLow-density Lipoprotein ParticlesLow-density Lipoprotein UptakeMacrophage ReceptorsScavenger Receptor-mediated UptakeScavenger Receptors
Atherosclerosis is an inflammatory disease in which oxidized low-density lipoprotein (oxLDL) plays important roles. Scavenger receptors (SR) CD36, SR-A, and LOX-1 uptake over 90% of the oxLDL leading to foam cell formation and secretion of inflammatory cytokines. To investigate whether the interindividual differences in macrophage SR gene expression could determine the inflammatory variability in response to oxLDL, we quantified the gene and protein expression of SR and inflammatory molecules from macrophages isolated from 18 volunteer subjects and incubated with oxLDL for 1, 3, 6, and 18 h. The individual gene expression profile of the studied SR at 1 h of incubation was highly variable, showing a wide fold-change range: CD36: -3.57-4.22, SR-A: -5.0-4.43, and LOX-1: -1.56-75.32. We identified subjects as high and low responders depending on whether their SR gene expression was above or below the median, showing a different inflammation response pattern. CD36 and LOX-1 gene expression correlated positively with IL-1beta; SR-A correlated negatively with IL-8 and positively with PPARgamma and NF-kappaBIotaA. These results were confirmed in the same subjects 3 mo after the first sampling. Furthermore, a negative correlation existed between CD36 and SR-A at protein level after 18 h of oxLDL incubation (R = -0.926, p = 0.024). These data would suggest that the type of SR could determine the macrophage activation: more proinflammatory when associated to CD36 and LOX-1 than when associated with SR-A.
19
C-Reactive Protein Levels and Outcomes after Statin Therapy
Paul M. Ridker, Christopher P. Cannon, David A. Morrow et al. · New England Journal of Medicine · 2005 · 2.3K citations · Full text
Vidya Kunjathoor, Maria Febbraio, Eugene A. Podrez et al. · Journal of Biological Chemistry · 2002 · 1K citations · Full text